| 25th November 2021 07:00PM To 08:30PM |
Article 1: Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS):a double-blind, randomised, placebo-controlled trial Lancet Neurol 2021; 20: 275–83 Article 2: Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. REMAP- CAP, ACTIV-4a, and ATTACC Investigators. N Engl J Med 2021; 385:777-789. |
